CCM
BPMC

Cinctive Capital Management’s Blueprint Medicines BPMC Stock Holding History

Cinctive Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-265,000
Closed -$34M – 407
2025
Q2 		$34M Buy
265,000
+233,806
+750% +$24.3M 1.8% 5
2025
Q1 		$2.76M Sell
31,194
-64,854
-68% -$6.33M 0.21% 138
2024
Q4 		$8.38M Buy
96,048
+21,707
+29% +$1.99M 0.43% 78
2024
Q3 		$6.88M Buy
74,341
+6,839
+10% +$679K 0.37% 90
2024
Q2 		$7.28M Buy
67,502
+9,157
+16% +$917K 0.35% 97
2024
Q1 		$5.53M Buy
58,345
+55,375
+1,864% +$4.75M 0.26% 120
2023
Q4 		$274K Buy
+2,970
New +$192K 0.02% 330

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Cinctive Capital Management's BPMC Position: Q3 2025 in Review

Cinctive Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 265,000 shares — an estimated $34M sold.

Cinctive Capital Management first reported a position in BPMC in Q4 2023 and held it in 7 quarters. The position peaked at $34M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Cinctive Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 265,000 Blueprint Medicines shares in Q3 2025, an estimated $34M.
  • Cinctive Capital Management first reported a position in Blueprint Medicines in Q4 2023 and held it in 7 quarters.
  • Cinctive Capital Management's Blueprint Medicines position peaked at $34M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.